EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
错误信息
- Notice: Undefined property: stdClass::$ds_changed 在 eval() (行 16 在 /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice: Undefined property: stdClass::$ss_search_api_url 在 eval() (行 20 在 /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice: Undefined property: stdClass::$tm_title 在 eval() (行 20 在 /var/www/7/modules/php/php.module(80) : eval()'d code).
The issuer is solely responsible for the content of this announcement.
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be highlighted during an oral presentation on Friday, May 31, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The congress is being held in Chicago, Illinois, from May 31 to June 4, 2024. Additionally, new data from the Phase 2 study of tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, in patients with advanced solid tumors or hematologic malignancies will be showcased in a poster presentation at ASCO 2024. ASCO 2024 Presentation Details
The full text of each abstract will be available on May 23 at 4:00 p.m. CDT. Please refer to the ASCO 2024 online program for full session details and data presentation listings. About MorphoSys About Pelabresib The development of pelabresib was funded in part by The Leukemia and Lymphoma Society®. About MANIFEST-2 Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others. Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor. About Myelofibrosis About Tulmimetostat For more information, please contact:
24.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | [email protected] |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1887399 |
End of News | EQS News Service |
|
1887399 24.04.2024 CET/CEST